ReviewStem cell reviews and reports2025
Stem Cell for Cancer Immunotherapy: Current Approaches and Challenges.
Review in Stem cell reviews and reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Rearming mesenchymal stem cells with engineering strategies to combat cancer.Frontiers in immunology · 2026Review
- Mesenchymal Stromal/Stem Cells (MSCs) in Cancer Therapy: Advanced Therapeutic Strategies Towards Future Clinical Translation.Molecules (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Stem cell-based immunotherapy represents a groundbreaking advancement in cancer treatment, leveraging the immune system's inherent capacity to target and eradicate cancer cells. This review explores some of the examples of stem cells used in cancer immunotherapy, including hematopoietic, mesenchymal, and induced pluripotent stem cells (IPSCs). It also describes stem cell functionalities like modifying tumor microenvironment (TME) and developing engineered immune cells like chimeric antigen receptor (CAR)-T cells and natural killer (NK) cells. Additionally, the clinical applications of stem cells for improving cancer immunotherapies and delivering drugs directly to solid tumors are discussed. However, several challenges limit the effectiveness of stem cell technology, including safety risks, tumor avoidance by the immune system, and regulatory protocols as well as manufacturing barriers. This article reviews current advancements to overcome these challenges, such as CRISPR-based gene editing and targeted drug delivery systems and provides an outlook on emerging trends, such as the progress of personalized stem cell therapies and the increasing effectiveness of treatment by combining them with other cancer treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.